000 | 01784 a2200577 4500 | ||
---|---|---|---|
005 | 20250517145911.0 | ||
264 | 0 | _c20180727 | |
008 | 201807s 0 0 eng d | ||
022 | _a1468-3288 | ||
024 | 7 |
_a10.1136/gutjnl-2016-312869 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHanin, Geula | |
245 | 0 | 0 |
_amiRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. _h[electronic resource] |
260 |
_bGut _c06 2018 |
||
300 |
_a1124-1134 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHyperlipidemias _xdrug therapy |
650 | 0 | 4 |
_aLipids _xblood |
650 | 0 | 4 |
_aLipogenesis _xdrug effects |
650 | 0 | 4 |
_aLiver _xmetabolism |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Obese |
650 | 0 | 4 | _aMice, Transgenic |
650 | 0 | 4 |
_aMicroRNAs _xantagonists & inhibitors |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNon-alcoholic Fatty Liver Disease _xdrug therapy |
650 | 0 | 4 |
_aOligonucleotides, Antisense _xpharmacology |
700 | 1 | _aYayon, Nadav | |
700 | 1 | _aTzur, Yonat | |
700 | 1 | _aHaviv, Rotem | |
700 | 1 | _aBennett, Estelle R | |
700 | 1 | _aUdi, Shiran | |
700 | 1 | _aKrishnamoorthy, Yoganathan R | |
700 | 1 | _aKotsiliti, Eleni | |
700 | 1 | _aZangen, Rivka | |
700 | 1 | _aEfron, Ben | |
700 | 1 | _aTam, Joseph | |
700 | 1 | _aPappo, Orit | |
700 | 1 | _aShteyer, Eyal | |
700 | 1 | _aPikarsky, Eli | |
700 | 1 | _aHeikenwalder, Mathias | |
700 | 1 | _aGreenberg, David S | |
700 | 1 | _aSoreq, Hermona | |
773 | 0 |
_tGut _gvol. 67 _gno. 6 _gp. 1124-1134 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1136/gutjnl-2016-312869 _zAvailable from publisher's website |
999 |
_c27053700 _d27053700 |